Fortis Healthcare Ltd (Fortis) owns, operates, and manages multi-specialty hospitals and super-specialty centers. It offers an array of healthcare services, including Cardiac Sciences, Geriatric Medicine, Oncology, Neurology, Liver Transplant, and Hepatobiliary Sciences, among others.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

The company’s R&D initiatives focused on evaluating new opportunities in clinical trials, contract evaluation services, and co-marketing initiatives. It has completed feasibility assessments for 16 esoteric clinical trial studies, successfully executing one clinical research study. Research proposals were developed for innovative miRNA-based biomarkers for cancer prognosis and screening of chronic endometriosis. Efforts were made to register the R&D division as an Evaluation Centre for Medical Devices and Diagnostics under The Central Drugs Standard Control Organisation (CDSCO), and the process for NABL 17025 accreditation was initiated. A collaborative study with Shalby Hospital, Ahmedabad, was conceptualized to evaluate advanced molecular diagnostics for prosthetic joint infections. A strategic tie-up with the Government of Gujarat was established for diagnosing multi-drug resistant tuberculosis using the First-Line Line Probe Assay (LPA) test. Additionally, the R&D team supported the development of a workflow to manage high-volume testing demands. The R&D unit of Fortis is responsible for exploring new tie-ups for clinical trials, contract evaluation services, and co-marketing projects. The unit also focuses on the registration and accreditation processes for medical device and diagnostic evaluations and supports the development of efficient workflows for testing demands.